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Hepatitis C virus infection strongly affects mitochondrial
DNA genetic diversity, which can be used to discriminate
recent from past infections.
BACKGROUND & AIMS: The host genetic environment con-
tributes signiﬁcantly to the outcomes of hepatitis C virus (HCV)
infection and therapy response, but little is known about
any effects of HCV infection on the host beyond any changes
related to adaptive immune responses. HCV persistence is
associated strongly with mitochondrial dysfunction, with liver
mitochondrial DNA (mtDNA) genetic diversity linked to disease
progression.
METHODS: We evaluated the genetic diversity of 2 mtDNA
genomic regions (hypervariable segments 1 and 2) obtained
from sera of 116 persons using next-generation sequencing.
RESULTS: Results were as follows: (1) the average diversity
among cases with seronegative acute HCV infection was 4.2
times higher than among uninfected controls; (2) the diversity
level among cases with chronic HCV infection was 96.1 times
higher than among uninfected controls; and (3) the diversity
was 23.1 times higher among chronic than acute cases. In 2
patients who were followed up during combined interferon and
ribavirin therapy, mtDNA nucleotide diversity decreased
dramatically after the completion of therapy in both patients:
by 100% in patient A after 54 days and by 70.51% in patient B
after 76 days.
CONCLUSIONS: HCV infection strongly affects mtDNA genetic
diversity. A rapid decrease in mtDNA genetic diversity
observed after therapy-induced HCV clearance suggests that
the effect is reversible, emphasizing dynamic genetic relation-
ships between HCV and mitochondria. The level of mtDNA
nucleotide diversity can be used to discriminate recent from
past infections, which should facilitate the detection of recent
transmission events and thus help identify modes of trans-
mission. (Cell Mol Gastroenterol Hepatol 2016;2:676–684;
http://dx.doi.org/10.1016/j.jcmgh.2016.05.012)
Keywords: Disease Biomarkers; mtDNA; Noninvasive.epatitis C virus (HCV) is a major public healthHproblem in the United States and worldwide. HCV
infects at least 3.5 million persons in the United States and
180 million persons worldwide.1 HCV infection is the most
common chronic blood-borne infection and the leading cause
for liver transplantation.2 Since 2007, HCV has surpassed
human immunodeﬁciency virus (HIV) as a cause of death in
the United States.3 Approximately 80% of patients who
become infected with HCV develop chronic hepatitis and are
at risk for advanced liver disease, with 15%–30% of these
patients progressing to liver ﬁbrosis and cirrhosis and up to
5% dying from liver failure or hepatocellular carcinoma
(HCC).2 The outcome of HCV infection is determined by a
complex interplay between host genetic, immunologic, and
viral factors.4 The host innate and adaptive immune re-
sponses are key determinants of viral clearance and persis-
tence. Several host genetic factors have been associated with
efﬁciency of immune response against HCV and with anti-
viral therapy outcome. The most well-known host genetic
factors affecting HCV infection are ethnic background,
interleukin 28B polymorphisms, and alleles of the inhibitory
natural killer cell receptor and HLA classes I and II.5 Recent
genome-wide association studies identiﬁed several new
factors inﬂuencing treatment efﬁcacy or clinical course of
HCV infection such as variants of interferon (IFN)L3-IFNL4,
IRAK2, DEPDC5, MICA, RNF7, TULP1, and MERTK.6,7
It is well established that viruses, which are simple
biological entities with high mutation rates, adapt rapidly to
the host genetic environment, producing distinct genetic
variants. In human beings, viral infections are not generally
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beyond those related to adaptive immune responses or rare
mutations associated with cancer,8 owing to the stability of
nuclear DNA. Mitochondrial DNA (mtDNA), however, varies
in copy number and has a high mutation rate.9
Chronic HCV infection has been associated strongly with
prominent mitochondrial injury of the liver.10–13 These ef-
fects include mitochondria swelling, loss of mitochondrial
cristae, reduction in number of mitochondria, calcium-
mediated mitochondrial depolarization and dysfunction,
and reactive oxygen species generation. Under normal cir-
cumstances, these impaired mitochondria would be elimi-
nated. However, in infected cells, HCV attenuates apoptosis
by cleaving mitochondrial antiviral signaling protein14 and
promoting mitochondrial ﬁssion and mitophagy of the
functionally compromised organelles,12,13 which contribute
to persistence of infection. These results are consistent with
the low mtDNA copy number found in the blood of persons
with chronic HCV infection.15 Oxidative stress and reactive
oxygen species generated by distressed mitochondria now
are recognized as a major procarcinogenic cofactor in
chronic HCV infection.10 In addition, mtDNA mutations were
found in the liver of patients with HCC16–22 and were linked
to outcomes of antiviral therapy.23
In this study, we used next-generation sequencing (NGS)
to evaluate the intrahost mtDNA variants from HCV-
uninfected persons and cases with seronegative acute and
seropositive chronic HCV infection. We show that the
mtDNA genetic diversity is higher in HCV-infected persons
and decreases after completion of therapy.Materials and Methods
Human Subjects
A total of 130 serum samples from 116 individuals
belonged to 4 groups. Groups 1 and 2 were obtained from
commercially available seroconversion panels (Seracare,
Milford, MA), and groups 3 and 4 were obtained through
clinical studies with Institutional Review Board approval,
with all patients providing written consent to participate.
The protocol was approved by Atlanta Medical Center’s
Institutional Review Board and the Icahn School of Medicine
at Mount Sinai (study ID: 06-0974 ME).
Group 1 comprised 50 HCV-uninfected (anti-HCV-
seronegative) plasma donors (control group). The samples
also were negative for anti-HIV and anti–hepatitis B virus. No
demographic or clinical information was available for this
group.
Group 2 comprised 18 plasma donors with seronegative,
polymerase chain reaction (PCR)-positive, acuteHCV infection.
In 12 cases, we analyzed 2 specimens obtained an average of
10.2 days apart, both before seroconversion. No demographic
or clinical information was available for this group.
Group 3 comprised 46 treatment-naive patients with
chronic HCV infection (anti-HCV-seropositive with PCR-
positive HCV infection for > 6 months). African American
(n ¼ 19), Caucasian (n ¼ 27); female (n ¼ 23), male (n ¼
23); noncirrhotic (n ¼ 28), cirrhotic (n ¼ 10); age at time of
specimen (n ¼ 45; range, 28–70 y; median, 53 y); steatosisabsent (n ¼ 24), steatosis present (n ¼ 13); genotype 1a
(n ¼ 28), genotype 1b (n ¼ 9), genotype 2 (n ¼ 7), genotype
3 (n ¼ 2); and HCV viral load quantiﬁed (n ¼ 39).
Group 4 comprised 2 HIV-infected men (designated pa-
tient A and patient B) with a recent HCV infection who
underwent successful therapy with peginterferon (pegIFN)
plus ribavirin. Two samples from each man were evaluated,
the ﬁrst from treatment baseline and the second from the
last HCV-positive sample during treatment. Patient A had
not seroconverted at baseline and patient B was anti-HCV-
positive at baseline, having seroconverted 0–7 days before.
Nucleic Acid Extraction
Blood was incubated in an upright position at room
temperature for 30–45 minutes to allow clotting. Then the
sample was centrifuged for 15 minutes at 2000 relative
centrifugal force to obtain serum. Total nucleic acid was
extracted from serum samples using the automated Roche
MagNA Pure LC robot and the MagNA Pure LC Total Nucleic
Acid Isolation kit (Roche Diagnostics, Indianapolis, IN), and
eluted with 50 mL of elution buffer according to the manu-
facturer’s instructions. Complementary DNA was generated
using the high-temperature capability SuperScript VILO
complementary DNA Synthesis Kit (Invitrogen, Life Tech-
nologies, Carlsbad, CA) on an ABI PRISM19700 PCR system
(Thermo Fisher Scientiﬁc, Waltham, MA).
mtDNA Ampliﬁcation
Hypervariable segment (HVS)1 and HVS2 in the D-loop
domain of mtDNA were analyzed. Two sets of primers
(external and nested) were used to amplify the HVS1 and
HVS2 regions of the mitochondrial D-loop: (1) for HVS1:
HVS1-H16401 (TGATTTCACGGAGGATGGTG),24 HVS1-L
15900 (TAAACTAATACACCAGTCTTGTAAACC),25 HVS1-
H16391 (GAGGATGGTGGTCAAGGGAC), and HVS1-L15997
(CACCATTAGCACCCAAAGCT)26; (2) for HVS2: HVS2-F-
16449 (CGCTCCGGGCCCATAACACTT), HVS2-R-722 (GAAC
TCACTGGAACGGGGATGCT), HVS2-F-44 (CATGCATTTGG
TATTTTCGTCTGG), and HVS2-R-638 (GGTGATGTGAGCC
CGTCTAA). For external primers, the following cycling
conditions were used: 95C for 150 seconds, 40 cycles of
94C for 1 minute, 55C for 30 seconds, and 72C for 1
minute. For the nested amplicons, PCR conditions were as
follows: 95C for 9 minutes, 36 cycles of 95C for 10 sec-
onds, 60C for 30 seconds, and 72C for 30 seconds (HVS1)
and 95C for 9 minutes, 36 cycles of 95C for 10 seconds,
52C for 30 seconds, and 72C for 30 seconds (HVS2). For
separation of PCR products, E-gel imager and E-gel size
select gel (2%) (cat# G661002; Invitrogen) were used. After
gel puriﬁcation, samples were run in a bioanalyzer (Agilent
2200 tape station, Agilent Techonologies, Santa Clara, CA) to
prepare for emulsion PCR.
NGS
PCR products were pooled and subjected to pyrose-
quencing using the GS FLX Titanium Sequencing Kit (454
Life Sciences, Roche Applied Sciences, Indiana, IN). Low-
quality reads were removed using the GS Run Processor
678 Campo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 5v2.3 (Roche). Initial reads were processed by matching to
the corresponding multiplex identiﬁer. The ﬁles then were
analyzed with the error correction algorithms KEC and ET,27
which have been validated to be highly accurate in ﬁnding
true haplotypes, estimating their frequencies and removing
false ones.
Data Analysis
For eachmtDNA amplicon, a multiple sequence alignment
was created by means of MAFFT,28 and then the primer se-
quences were trimmed, yielding a ﬁnal amplicon of 433 base
pairs for HVS1 and 502 base pairs for HVS2. The level of
genetic diversity in each sample was examined by unbiased
estimates of nucleotide diversity, calculated according to Nei
and Li29 using MATLAB.30 All other statistical analyses were
performed with IBM SPSS statistics for windows.31 Compar-
ison among groups was performed with the independent
samples median test, which tests the null hypothesis that the
medians are equivalent across groups. To test the median of
differences between the 2 time points of acute samples, we
used the related samples Wilcoxon signed-rank test. Box
plots show theminimum,ﬁrst quartile,median, third quartile,
and maximum of the distribution of values. A receiver oper-
ating characteristic (ROC), or ROC curve, was built, which
illustrates the performance of a binary classiﬁer (eg, acute vs
chronic samples) because the mtDNA nucleotide diversity
threshold varied, plotting the true-positive rate against the
false-positive rate at various threshold settings.
Monte–Carlo Sampling
To establish the effect of sampling depth on the mtDNA
nucleotide diversity, a Monte–Carlo sampling method was
used. For each sample, 5% of the total number of reads were
sampled randomly from the original ﬁle, and the nucleotide
diversity of the subsamples was calculated. This procedure
was repeated 1000 times for each sample, alsowith a different
number of reads (from 5% to 100%, in increments of 5%).
Network Visualization
We built a k-step network as previously described by
Campo et al32 using MATLAB.30 The k-step network con-
tains all possible minimum spanning trees and allows efﬁ-
cient visualization of the genetic relatedness among all
haplotypes present in the sample. The networks were
drawn with GEPHI.33Table 1.Mean Values for All Samples of Each Group
Samples, n
Nucleotide diversity,
mean (SEM)
Nucleotide
diversity, media
Controls HVS1 50 1.99E-05 (6.08E-06) 0.00Eþ00
Acute HVS1 18 8.25E-05 (2.10E-05) 7.15E-05
Chronic HVS1 46 1.96E-03 (2.04E-04) 2.16E-03
Controls HVS2 50 2.67E-04 (3.22E-05) 2.33E-04
Acute HVS2 18 1.23E-04 (4.61E-05) 7.77E-05
Chronic HVS2 46 1.07E-03 (1.29E-04) 7.05E-04
Total 228 6.90E-04 (6.92E-05) 2.32E-04Results
NGS of mtDNA
A total of 258,503 and 75,515 NGS reads were obtained
from HVS1 and HVS2, respectively, the 130 serum speci-
mens. On average, 2039.49 HSV1 reads (SEM, 278.21) were
sampled from each specimen. Although the number of reads
varied among persons (Table 1), no statistically signiﬁcant
difference in the median number of reads (P ¼ .069) was
found among the study groups (P ¼ .069). For HVS2, how-
ever, the average number of reads per sample was much
lower (n ¼ 638.55; SEM, 74.20), and there were statistically
signiﬁcant differences in the median number of reads
among groups (P < .001).
Nucleotide diversity, which is deﬁned as the average
number of nucleotide differences per site between any 2 DNA
sequences chosen randomly from the sample population,
was calculated. Although estimates of nucleotide diversity of
intrahost variants are robust to the sample size varia-
tions,34,35 reliability of the estimates also may vary depend-
ing on the genetic heterogeneity of tested populations.
Considering the observed variation in the number of reads
obtained from each group, the effect of the read sample size
on the measured nucleotide diversity was evaluated using
Monte–Carlo sampling for both HVS1 and HVS2 for each
group. The data show that the NGS sampling depth has very
little effect on the measured nucleotide diversity, with even
10% of the reads providing estimates that were very similar
to those obtained from full-size samples (Figure 1A and B).
Samples with low mtDNA nucleotide diversity (controls and
cases with seronegative acute HCV infection) were less
affected by changes in sample size, whereas estimates of
nucleotide diversity for more heterogeneous populations
(cases with chronic HCV infection) did not converge, indi-
cating that a greater sample size is required for accurate
estimates. However, the value of nucleotide diversity in the
last group rapidly increased with the increase in sample size
and achieved 75%–80% of the value of the full-size sample at
only 25% of sampled sequences.
mtDNA Is More Heterogeneous in HCV-Infected
Persons Than in Healthy Controls
A predominant major variant was found in all samples
that corresponds to the germline mtDNA sequence. How-
ever, the frequency of the major variant differed among the
groups. Controls and acute cases had the highest values,n
Sequences,
n (SEM) Reads, n (SEM)
Major sequence,
% (SEM)
Mutants,
% (SEM)
1.52 (0.19) 865.20 (187.65) 99.57 (0.13) 0.43 (0.13)
2.11 (0.28) 1092.61 (126.43) 98.25 (0.43) 1.75 (0.43)
559.22 (87.46) 3686.41 (579.88) 64.76 (3.26) 35.24 (3.26)
3.06 (0.20) 352.98 (40.97) 93.07 (0.85) 6.93 (0.85)
2.00 (0.20) 202.06 (45.07) 96.79 (1.21) 3.21 (1.21)
86.37 (21.35) 1119.76 (152.32) 76.59 (2.66) 23.41 (2.66)
131.58 (23.08) 1339.02 (150.99) 86.16 (1.24) 13.84 (1.24)
Figure 1. Monte–Carlo
sampling. (A) HVS1 and
(B) HVS2 samples.
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(Table 1 and Figure 2). In concordance with the frequency
of major variants, it was found that the average level of
HVS1 mtDNA nucleotide diversity in chronic cases was 98.5
times higher than in controls (P < .001) and was 4.2 times
higher in cases with seronegative acute HCV infection than
in controls (P ¼ .001) (Table 1). Higher nucleotide diversity
of HVS2 in chronic cases also was found, with the average
level of HVS2 mtDNA nucleotide diversity 4 times higher
than in controls (P < .0001). The average diversity of acute
cases was numerically but not signiﬁcantly lower than in
controls (P ¼ .054) (Figure 3), although the distributions
were markedly different (independent samples Man-
n–Whitney test, P ¼ .005).High mtDNA Diversity in Cases With
Chronic HCV Infection
The average mtDNA HVS1 nucleotide diversity among
chronic cases was 23.7 times higher than among acute cases
(P < .001) (Table 1). However, the average total number of
reads obtainedwas not statistically different between these 2
groups (P ¼ .120). The average HVS2 mtDNA nucleotide di-
versity among chronic caseswas 8.7 times higher than among
acute cases (P < .001). The correlation between nucleotidediversity values for HVS1 and HVS2 obtained for all patients
was highly signiﬁcant but moderate (r ¼ 0.441, P ¼ .0001),
indicating that both mtDNA regions experienced genetic
diversiﬁcation during HCV infection but at different rates.
The differences in mtDNA heterogeneity suggest that the
degree of HVS1 nucleotide diversity could be used to
discriminate between acute and chronic HCV infection. The
ROC curve in Figure 4 shows performance of a simple bi-
nary classiﬁer based on the mtDNA nucleotide diversity
threshold, which allows for distinguishing acute from
chronic samples with 100% sensitivity and 84.8% speci-
ﬁcity (area under the curve [AUC], 0.9577) (Table 2). A
similar approach can be used to distinguish controls from
chronic samples (AUC, 0.9887) and controls form acute
samples (AUC, 0.7172).
There was no signiﬁcant difference in nucleotide di-
versity of either HVS1 or HVS2 over the short time (mean,
10.2 days; range, 2–21 days) between the paired specimens
from 12 acute cases. Although the average nucleotide di-
versity was found to be 3.2 and 1.4 times higher for HVS1
and HVS2, respectively, at the second time points, these
differences were not statistically signiﬁcant for both regions
(HVS1, P¼ .327; HVS2, P¼ .695). There was not a signiﬁcant
correlation between the differences in nucleotide diversity
and time for HVS1 (r ¼ 0.075, P ¼ .816) as well as for HVS2
Figure 2. K-step net-
works of 2 HCV samples.
Each node is a different
mtDNA HVS1 variant and 2
nodes are linked if they
differ in a single nucleotide.
The size of the node is
proportional to the square
root of the frequency of
that particular variant. The
grey node is the major
variant and the black
nodes are mutant variants.
(A) Acute sample from an
individual with mtDNA
nucleotide diversity close
to the median of the acute
group (7.15E-05). (B)
Chronic sample from an
individual with mtDNA
nucleotide diversity close
to the median of the
chronic group (2.16E-03).
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accumulation of detectable genetic heterogeneity in serum
mtDNA. Nonetheless, the threshold-based binary classiﬁer
correctly classiﬁed all of the follow-up specimens as acute.
Analysis of the HVS1 nucleotide diversity from 46
chronic cases, for whom clinical and demographic data were
available, showed no association with ethnicity (P ¼ .194),
sex (P ¼ .111), HCV genotypes (1 vs 2; P ¼ .099), HCV
subgenotypes (1a vs 1b; P ¼ .926), steatosis (P ¼ .863), or
cirrhosis (P ¼ .182). However, for all variables the sampleFigure 3. Box plot of the nucleotide diversity values of
mtDNA samples.sizes were smaller than the minimum needed to ﬁnd sig-
niﬁcant differences (a ¼ .05; power ¼ 0.80). In addition,
there was no signiﬁcant correlation with age (Pearson cor-
relation, r ¼ 0.072, P ¼ .636) or viral load (Pearson corre-
lation, r ¼ 0.114, P ¼ .491).
Reduction of mtDNA Diversity After
Antiviral Therapy
To assess the effect of a pegIFNþ ribavirin treatment-
associated decrease in HCV viremia on mtDNA nucleotide
diversity, paired specimens from 2 HIV-infected men withFigure 4. ROC curve of the mtDNA nucleotide diversity
binary classiﬁer.
Table 2.Classiﬁcation Performance of a Nucleotide Diversity Cut-Off Value
Ratio of the
means
Independent samples,
median test (P value) AUC
Sensitivity
(%)
Speciﬁcity
(%)
Nucleotide diversity
cut-off value
Chronic HVS1/ acute HVS1 23.71 .0001 0.9577 100 84.78 3.20E-04
Chronic HVS1/ controls HVS1 98.53 .0001 0.9887 100 91.3 2.20E-04
Acute HVS1/ controls HVS1 4.16 .001 0.7172 82 61.11 5.00E-05
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reads was obtained from each sample: 3954 and 1222
from patient A and 6163 and 2853 from patient B. The
effect of the sample size on robustness of the nucleotide
diversity using Monte–Carlo sampling showed that the
sample of sequences from each specimen was adequate for
representation of the nucleotide diversity (Figure 5A). The
mtDNA nucleotide diversity decreased dramatically after
therapy in both patients: by 100% in patient A after 54
days and by 70.51% in patient B after 76 days (Figure 5B),
which can be seen in the sequence networks (Figure 5C
and D).
Discussion
There are many reports on the signiﬁcant role of human
genetics in determining the outcomes of HCV infection,
antiviral therapy, and the genetic composition of intrahost
HCV populations.4–7 However, little is known about any
effects of HCV infection on the host genetics beyond any
changes related to adaptive immune responses, although
interacting genetic systems should affect each other
mutually. It is assumed that nuclear DNA is genetically
stable and does not change genetically in HCV-infected
cells, although mtDNA is known to vary genetically,
owing to a high mutation rate. We show through NGS that
the genetic diversity of 2 mtDNA regions, HVS1 and HVS2,
is higher in sera of HCV-infected persons than in healthy
controls.
Sampling Depth and Nucleotide Diversity
Application of NGS to sequencing intrahost genetic var-
iants presents several new challenges, including the repre-
sentational depth of sequence samples. In our experiments,
the number of reads varied among groups of specimens.
However, sampling differences were statistically signiﬁcant
only for HVS2. Such variation potentially may affect esti-
mates of genetic diversity. To reduce the effect of sampling
variation, we used nucleotide diversity, which was shown to
be minimally dependent on the sample size.34,35 For
instance, estimates of HCV nucleotide diversity were found
to be almost identical between samples of dozens or thou-
sands of reads.34 This ﬁnding was conﬁrmed in this study
for the NGS samples of both HVS1 and HVS2 using the
Monte–Carlo sampling method (Figure 1). The sampling
depth was shown to have a limited effect on the measure of
nucleotide diversity, with only 10%–25% of reads from full
samples closely approximating all observations made in this
study for acute and chronic groups of specimens.Acute and Chronic Stages of HCV Infection
Currently, seroconversion and detection of HCV RNA in
serial specimens are the only reliable markers of acute HCV
infection. The avidity index of IgG anti-HCV36 and patterns
of IgG anti-HCV responses to several structural and
nonstructural HCV proteins37 recently were evaluated for
discrimination of acute from chronic infection. Genetic di-
versity of the hypervariable region 138,39 and nonstructural
5B protein40 also were used to detect acute infections.
However, none of the developed approaches detects stages
of HCV infection with high accuracy. Unfortunately, the
application of HCV genetic diversity to the detection of acute
infection is not straightforward because of the complex
dynamics of intrahost HCV populations, which are organized
into several communities,32 each varying in density during
infection.41 Although in general the degree of HCV genetic
heterogeneity increases over time during infection, these
genetic changes vary among patients, depending on many
factors such as the number of founders and communities,
genetic distances among communities, strength and speci-
ﬁcity of immune responses, and host genetics, which usually
are unknown or difﬁcult to establish.
In contrast to the complex intrahost HCV population dy-
namics, genetic changes in the intrahost mtDNA population
easily can be traced to a single known germline mtDNA
sequence. mtDNA variants are organized in a single cluster,
with genetic heterogeneity of the cluster being much higher
in patients with chronic HCV infection. This property signif-
icantly facilitates application of the mtDNA genetic diversity
to the discrimination of acute and chronic stages of HCV
infection. Indeed, we have shown that a simple binary clas-
siﬁer based on the mtDNA nucleotide diversity threshold
allows for accurate distinguishing of acute and chronic
samples, indicating its utility for timing HCV infection and for
the detection of recent transmission events, thus improving
chances for timely public health interventions to disrupt HCV
dissemination, especially in health care settings.
Analysis of the mtDNA nucleotide diversity in follow-up
serum specimens from 2 patients who cleared HCV infection
after combined treatment with pegIFN and ribavirin showed
that the mtDNA diversity detectable in serum may decrease
as fast as it increases after inception of infection. This
ﬁnding supports the earlier observations of reduction of
somatic mtDNA mutations in liver tissue of chronically HCV-
infected patients with HCC after interferon treatment.23,42
Although reduction of mtDNA heterogeneity was attrib-
uted to interferon treatment,23,42 the increased level of
mtDNA genetic diversity found in cases with HCV infection
suggests a direct role of HCV in the presentation of mtDNA
Figure 5. mtDNA diversity of 2 followed up HCV samples. (A) Monte–Carlo sampling and nucleotide diversity. (B) Nucleotide
diversity on 2 patients who were followed up. The values of patient A are shown in grey, whereas the values of patient B are
shown in black. (C and D) K-step networks. Each node is a different mtDNA HVS1 variant and 2 nodes are linked if they differ in
a single nucleotide. The size of the node is proportional to the square root of the frequency of that particular variant. The gray
nodes correspond to mtDNA variants that were found before and after therapy. White nodes correspond to mtDNA variants
that were present only before therapy.
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diversity with the success of anti-HCV treatment. However,
the number of mtDNA mutations detectable in serum and
liver may differ considerably,23,42 indicating that compari-
son between observations made in different tissues should
be interpreted with caution.
Study Limitations
Nucleotide diversity estimated for short genomic regions
may not represent the genetic diversity of the entire mtDNA
accurately. Hence, all observations presented here should be
extrapolated with caution to the whole genome of mito-
chondria. However, the selection of speciﬁc primers for
short-amplicon sequencing has an advantage of limiting the
contribution of nuclear mtDNA insertions to the measured
nucleotide diversity. Although more extensive analysis of
the mitochondrial genome may show greater complexity of
genetic associations with HCV infection, the ﬁndings made
for HVS1 and HVS2 are statistically signiﬁcant and can be
explored for the identiﬁcation of stages of HCV infection.All ﬁndings made in this study reﬂect the accumula-
tion of mutant mtDNA species in serum and may not be
completely applicable to samples of liver tissue. The
origin of mtDNA and its genetic variants in serum is not
well understood, beyond the fact that both particle-
associated and free mtDNA are known to be present in
plasma,43 a phenomenon that has been exploited since
the early efforts to detect cancer-related mitochondrial
mutants in serum.44 Further studies on the origin of
mtDNA variants detected in serum during HCV infection
are needed, knowledge that can be used to ascertain if the
increase in nucleotide diversity observed here is caused
by either the variation in frequency among different pre-
existing mitochondrial populations, mtDNA of which be-
comes represented most abundantly in the blood during
HCV infection; and/or HCV-induced reduction in
mitochondria-mediated apoptosis, resulting in accumu-
lation of impaired mitochondria and their mtDNA vari-
ants in infected hepatocytes, which eventually can be
found in blood.
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HCV infection strongly affects mtDNA genetic diversity,
with the effect being most pronounced at later stages of HCV
infection. A rapid decrease in the mtDNA genetic diversity
observed after the therapy-induced HCV clearance suggests
that the effect is reversible, emphasizing dynamic genetic
relationships between HCV and mitochondria. These ﬁnd-
ings suggest applications of mtDNA genetic diversity as a
novel noninvasive biomarker to stage HCV infection and to
monitor therapy effectiveness.
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